Inari Medical Inc Ordinary Shares NARI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Kaskela Law LLC Announces Shareholder Investigation of Inari Medical, Inc. (NASDAQ: NARI) and Encourages Long-Term NARI Shareholders to Contact the Firm
-
Kaskela Law LLC Announces Shareholder Investigation of Inari Medical, Inc. (NASDAQ: NARI) and Encourages Investors to Contact the Firm
-
Inari Medical Announces PEERLESS Data to be Presented During the Late-Breaking Clinical Trial Sessions at TCT 2024
-
Inari Medical to Present at Upcoming Investor Conferences
-
Inari Medical Announces Chief Financial Officer Retirement and Succession Plan
-
Inari Medical Reports Second Quarter 2024 Financial Results
-
Inari Medical to Announce Second Quarter 2024 Financial Results
-
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Inari Medical, Inc. – NARI
Trading Information
- Previous Close Price
- $42.84
- Day Range
- $41.59–43.06
- 52-Week Range
- $36.72–69.41
- Bid/Ask
- $42.08 / $42.15
- Market Cap
- $2.45 Bil
- Volume/Avg
- 523,341 / 884,074
Key Statistics
- Price/Earnings (Normalized)
- 460.04
- Price/Sales
- 4.52
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Inari Medical Inc is a medical device company focused on developing products to treat patients suffering from Chronic Venous Disease. Its product portfolio includes; ClotTriever, for the removal of the clot from peripheral blood vessels and treats patients suffering from deep vein thrombosis. The FlowTriever System product is used for the treatment of pulmonary embolism, InThrill system to treat small vessel thrombosis, LimFlow system and others. Geographically, the company generates majority of its revenue from United States and rest from International markets.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Growth
- Total Number of Employees
- 1,300
- Website
- https://www.inarimedical.com
Comparables
Valuation
|
Metric
|
NARI
|
AXNX
|
LUNG
|
|---|---|---|---|
Price/Earnings (Normalized) | 460.04 | 604.07 | — |
Price/Book Value | 5.88 | 5.51 | 2.88 |
Price/Sales | 4.52 | 8.52 | 3.74 |
Price/Cash Flow | 345.21 | 110.45 | — |
Price/Earnings
NARI
AXNX
LUNG
Financial Strength
|
Metric
|
NARI
|
AXNX
|
LUNG
|
|---|---|---|---|
Quick Ratio | 1.38 | 7.01 | 7.75 |
Current Ratio | 1.80 | 8.96 | 8.97 |
Interest Coverage | −164.83 | — | −16.66 |
Quick Ratio
NARI
AXNX
LUNG
Profitability
|
Metric
|
NARI
|
AXNX
|
LUNG
|
|---|---|---|---|
Return on Assets (Normalized) | −1.37% | 5.50% | −21.96% |
Return on Equity (Normalized) | −1.89% | 6.16% | −33.26% |
Return on Invested Capital (Normalized) | −3.24% | 3.86% | −25.19% |
Return on Assets
NARI
AXNX
LUNG
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| Dtdtmnzz | Xzvmw | $197.7 Bil | |||
| Stryker Corp
SYK
| Crwlbsbvd | Czx | $135.3 Bil | |||
| Boston Scientific Corp
BSX
| Zzsxrkrs | Whhgdp | $124.4 Bil | |||
| Medtronic PLC
MDT
| Crdhdxv | Mvrqxp | $114.3 Bil | |||
| Edwards Lifesciences Corp
EW
| Cpwtphqsc | Sqrhv | $39.2 Bil | |||
| Koninklijke Philips NV ADR
PHG
| Fzwr | Rmlx | $30.2 Bil | |||
| DexCom Inc
DXCM
| Wzvpcwtb | Ndslz | $26.9 Bil | |||
| Steris PLC
STE
| Dltpylb | Lcgdtv | $23.1 Bil | |||
| Zimmer Biomet Holdings Inc
ZBH
| Qskrvmwg | Tmvym | $21.5 Bil | |||
| Insulet Corp
PODD
| Vbwwbbwhg | Bzqshx | $16.3 Bil |
United States